Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Receivables (2016 - 2025)

Historic Receivables for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $44.4 million.

  • Angiodynamics' Receivables rose 295.66% to $44.4 million in Q4 2025 from the same period last year, while for Nov 2025 it was $44.4 million, marking a year-over-year increase of 295.66%. This contributed to the annual value of $42.9 million for FY2025, which is 165.1% down from last year.
  • As of Q4 2025, Angiodynamics' Receivables stood at $44.4 million, which was up 295.66% from $42.6 million recorded in Q3 2025.
  • Over the past 5 years, Angiodynamics' Receivables peaked at $53.6 million during Q3 2022, and registered a low of $33.2 million during Q1 2021.
  • Its 5-year average for Receivables is $44.9 million, with a median of $43.5 million in 2024.
  • As far as peak fluctuations go, Angiodynamics' Receivables soared by 5130.45% in 2022, and later crashed by 2048.44% in 2024.
  • Angiodynamics' Receivables (Quarter) stood at $38.2 million in 2021, then soared by 38.34% to $52.9 million in 2022, then fell by 2.36% to $51.6 million in 2023, then dropped by 16.37% to $43.2 million in 2024, then rose by 2.96% to $44.4 million in 2025.
  • Its Receivables stands at $44.4 million for Q4 2025, versus $42.6 million for Q3 2025 and $42.9 million for Q2 2025.